DUBLIN, Jan. 16, 2023 /PRNewswire/ — The “Global Dry Eye Syndrome Treatment Market Size, Share & Industry Trends Analysis Report by Type, Drug, Dosage, Distribution Channel, Sales Channel, Product, Regional Outlook and Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering.
The Global Dry Eye Syndrome Treatment Market size is expected to reach $6.5 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.
For clear eyesight, the tear film is crucial. Three layers comprise the tear film: an oily layer, a watery layer, and a mucus layer with each layer having a specific function. The exterior of the tear film is the oily layer. It smoothens the tear’s surface and slows down the rate of drying.
The meibomian glands in the eye produce this layer. The center of the tear film is the watery layer. The majority of what is perceived as tears is made up of them. By removing foreign objects from the eye, this layer cleanses the eye. The lacrimal glands present in eyelids produce this layer.
The innermost layer of the film is called the mucus layer. This aids in distributing the watery layer and maintaining the eye’s moisture.
Tears would not adhere to the eye without mucus, which is produced by the conjunctiva. This is the transparent tissue that lines the interior of the eyelids and the surface of the eye. Normal tear production keeps eyes moist all the time. The eyes produce a lot of tears when they are inflamed or when someone cries.
COVID-19 Impact Analysis
Due to fewer ophthalmologist appointments, the COVID-19 pandemic had a negative effect on the dry eye syndrome treatment market in the initial stages of the pandemic. But as immediately as the eye care businesses started, the market started to recover.
Additionally, the prevalence of dry eye complaints has grown throughout the pandemic due to increased screen use and sedentary lifestyles. The extrapolation of the results of these cases makes it evident that COVID-19 has a positive impact on the market.
Market Growth Factors
Development of promising drugs to manage Dry Eye Diseases
In various age categories, the estimated concentration ranges from roughly 5% to over 35%. Dry eye (DE) is usually overlooked despite being very common. Dry Eye is a significant burden on the public healthcare system because of its detrimental effects on patients’ visual function and life quality.
Therefore, efforts to improve diagnostic procedures and develop suitable DE treatments are merited. Reproxalap (Alderya Therapeutics), tivanisiran (Sylentis), tanfanercept (HanAll BioPharma), timbetasin (Regenerx), loteprednol etabonate (Kala Pharma), and NOV03 (Bausch + Lomb) are few of the medications that were recently investigated in Phase 3 trials for the treatment of dry eyes. As these development continue to proceed, they aid in the expansion of the dry eye syndrome treatment market.
Availability of different procedures and medicines to suit the majority
Burning, Itching, irritation, eye tiredness, and ocular inflammation are among the prominent symptoms of DED, which can vary from mild to serious and can potentially cause impairment to the cornea, conjunctiva, and even loss of eyesight.
As a result, the treatment must be customized to each patient by focusing on the distinct mechanisms linked to their condition, depending on the various presentations and pathophysiology. The tailoring of the medical procedure allows patients to think about the pros and cons before going for treatment.
This provides satisfaction and additional comfort to patients which tremendously helps in the success of treatment. This, in turn, will bolster the growth of the dry eye syndrome treatment market.
Market Restraining Factors
Drug approval takes a longer time
Drug approval entails several expensive regulatory approvals and research phases. About four steps of clinical trials are involved in the drug approval process, as well as different stages of screening by regulatory agencies like the FDA. Because clinical trial phases need significant investments, the costs of unsuccessful trials are also large.
For instance, a Forbes article estimates that a drug manufacturer spends roughly $350 million on each treatment before it is introduced to the market. This demonstrates significant drug approval costs that are expected to have an impact on the market for dry eye medications. Additionally, long waiting times also add up to lost money for these manufacturers, and as such hampers the growth of the dry eye syndrome treatment market.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
18.104.22.168 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis – Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. Global Dry Eye Syndrome Treatment Market by Type
4.1 Global Evaporative Dry Eye Syndrome Market by Region
4.2 Global Aqueous Deficient Dry Eye Syndrome Market by Region
Chapter 5. Global Dry Eye Syndrome Treatment Market by Drug
5.1 Global Restasis Market by Region
5.2 Global Xiidra Market by Region
5.3 Global Cequa Market by Region
5.4 Global Eysuvis Market by Region
5.5 Global Tyrvaya & Others Market by Region
Chapter 6. Global Dry Eye Syndrome Treatment Market by Dosage
6.1 Global Eye drops Market by Region
6.2 Global Gels Market by Region
6.3 Global Capsules & Tablets Market by Region
6.4 Global Eye Solutions Market by Region
6.5 Global Ointments Market by Region
Chapter 7. Global Dry Eye Syndrome Treatment Market by Distribution Channel
7.1 Global Retail Pharmacy Market by Region
7.2 Global Hospital Pharmacy Market by Region
7.3 Global Online Pharmacy Market by Region
Chapter 8. Global Dry Eye Syndrome Treatment Market by Sales Channel
8.1 Global OTC Market by Region
8.2 Global Prescription Market by Region
Chapter 9. Global Dry Eye Syndrome Treatment Market by Product
9.1 Global Cyclosporine Market by Region
9.2 Global Topical Corticosteroids Market by Region
9.3 Global Artificial Tears Market by Region
9.4 Global Punctal Plugs Market by Region
9.5 Global Oral Omega Supplements Market by Region
9.6 Global Others Market by Region
Chapter 10. Global Dry Eye Syndrome Treatment Market by Region
Chapter 11. Company Profiles
11.1 Johnson & Johnson (Johnson & Johnson Services, Inc.)
11.1.1 Company Overview
11.1.2 Financial Analysis
11.1.3 Segmental &Regional Analysis
11.1.4 Research & Development Expenses
11.1.5 Recent strategies and developments:
22.214.171.124 Product Launches and Product Expansions:
126.96.36.199 Approvals and Trials:
11.1.6 SWOT Analysis
11.2 AbbVie, Inc.
11.2.1 Company Overview
11.2.2 Financial Analysis
11.2.3 Regional Analysis
11.2.4 Research & Development Expense
11.2.5 Recent strategies and developments:
188.8.131.52 Partnerships, Collaborations, and Agreements:
184.108.40.206 Product Launches and Product Expansions:
11.3 Bausch + Lomb Corporation (Bausch Health Companies, Inc.)
11.3.1 Company Overview
11.3.2 Financial Analysis
11.3.3 Segmental and Regional Analysis
11.3.4 Research & Development Expense
11.3.5 Recent strategies and developments:
220.127.116.11 Partnerships, Collaborations, and Agreements:
18.104.22.168 Product Launches and Product Expansions:
11.4 Novartis AG
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Segmental and Regional Analysis
11.4.4 Research & Development Expense
11.4.5 Recent strategies and developments:
22.214.171.124 Acquisition and Mergers:
11.5 Sun Pharmaceuticals Industries Ltd
11.5.1 Company Overview
11.5.2 Financial Analysis
11.5.3 Regional Analysis
11.5.4 Research & Development Expenses
11.5.5 Recent strategies and developments:
126.96.36.199 Product Launches and Product Expansions:
188.8.131.52 Approvals and Trials:
11.6 AFT Pharmaceuticals
11.6.1 Company Overview
11.6.2 Financial Analysis
11.6.3 Segmental Analysis
11.6.4 Research & Development Expenses
11.6.5 Recent strategies and developments:
184.108.40.206 Product Launches and Product Expansions:
11.7 Santen Pharmaceutical Co., Ltd.
11.7.1 Company Overview
11.7.2 Financial Analysis
11.7.3 Regional Analysis
11.7.4 Research & Development Expenses
11.7.5 Recent strategies and developments:
220.127.116.11 Acquisition and Mergers:
18.104.22.168 Approvals and Trials:
11.8 Oyster Point Pharma, Inc.
11.8.1 Company Overview
11.8.2 Financial Analysis
11.8.3 Research & Development Expenses
11.8.4 Recent strategies and developments:
22.214.171.124 Partnerships, Collaborations, and Agreements:
126.96.36.199 Approvals and Trials:
11.9 OASIS Medical, Inc.
11.9.1 Company Overview
11.9.2 Recent strategies and developments:
188.8.131.52 Product Launches and Product Expansions:
11.10. Otsuka Pharmaceutical Co., Ltd.
11.10.1 Company Overview
For more information about this report visit https://www.researchandmarkets.com/r/j3p0ey
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/the-worldwide-dry-eye-syndrome-treatment-industry-is-expected-to-reach-6-5-billion-by-2028–301721286.html
SOURCE Research and Markets
Discover why two FAANG stocks are poised to bounce back in 2023 and beat the market with their current spring-loaded share price discounts, while another looks like a questionable idea today.
Futures were mixed, with U.S. markets closed for the Martin Luther King Holiday. Time to act, carefully, as the rally clears resistance. Tesla faces a big transition.
The chip sector is getting back on its proverbial feet after a challenging period, but not every stock is a winner.
Sin is in.
Historically, in the first positive year following a loss, the Nasdaq-100 returned between 37% and 64%, or an average of 51% across the four instances in 1991, 2003, 2009, and 2019. Microsoft (NASDAQ: MSFT) is one of the safest bets on Wall Street and gets praise from analysts and retail investors alike. Microsoft has billions of customers using its legacy software products like the Windows operating system and the Office 365 document suite, but its business is now more diverse than ever.
Don’t just consume food, invest in it.
Recently, Zacks.com users have been paying close attention to AT&T (T). This makes it worthwhile to examine what the stock has in store.
During the previous long bull market, dividends were an afterthought for many investors. More investors now realize just how important dividends can be. There are lots of great dividend stocks out there.
Warren Buffett has a case for the title of the greatest investor of all time; understandably, a $110 billion net worth gets you a lot of respect. The Oracle of Omaha owns many stocks, but it could be his holding in Bank of America (NYSE: BAC) that gets me the most excited. Or, more importantly, why should you get excited about Bank of America stock?
In this video, I will be talking about Alibaba (NYSE: BABA), specifically some new price targets from analysts, and how things could evolve in 2023 now that China is reopening. For the full insights, watch the video, consider subscribing, and click the special offer link below.
Time to boost your financial knowledge.
The bear market of 2022 was especially tough on the tech-heavy Nasdaq Composite. While the S&P 500 ended the year down by 19%, the Nasdaq closed out 2022 down by 33%. Caught up in that broad downtrend was cybersecurity company CrowdStrike (NASDAQ: CRWD).
It would have been nearly impossible to predict the events of last year. Let's see if 2023 will be any easier.
Based on the average brokerage recommendation (ABR), SoFi Technologies, Inc. (SOFI) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
The Boeing Company, Textron, Lockheed and Northrop Grumman are part of the Zacks top Analyst Blog.
Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet's Quant Ratings, we zero in on three names. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. Greenbrier Companies recently was downgraded to Hold with a C rating by TheStreet's Quant Ratings.
If someone close to you has died, the last thing you may want to talk about is money. However, in order to honor their final wishes, you'll need to follow their will (if they left one) or potentially go to … Continue reading → The post How to Deposit a Large Cash Inheritance appeared first on SmartAsset Blog.
Is crypto really the new gold?
In this article, we discuss 12 best holding company stocks to invest in. If you want to see more stocks in this selection, check out 5 Best Holding Company Stocks To Invest In. A holding company is a business entity, usually a corporation or limited liability company, that does not directly manufacture products, offer any […]
Recently, Zacks.com users have been paying close attention to Devon Energy (DVN). This makes it worthwhile to examine what the stock has in store.